Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLBS1449
- Development stage
- Preclinical
- Lead developer
- Dexa Laboratories of Biomolecular Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DLBS1449 is a natural extract derived from the fruit of *Phaleria macrocarpa*, developed by Dexa Medica Group. It is being investigated primarily for its potential to treat dyslipidemia and low HDL-cholesterol, particularly in diabetic patients. The main mechanism of action identified for DLBS1449 is inhibition of cholesteryl ester transfer protein (CETP), which plays a role in lipid metabolism and HDL regulation. As a plant-derived small molecule, it represents a novel approach to managing lipid disorders[1][2][3][4]. Clinical studies have evaluated its efficacy in increasing HDL-cholesterol levels[3][4].
- Other names
- Phaleria macrocarpa extract
02
Targets
CETP
Beyond the preview
Go deeper on DLBS1449.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLBS1449.